EVOTEC

DE0005664809

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of December 31, 2019, Evotec had a market capitalization of €3.47 billion and a pipeline of more than 100 partnered programs in discovery, pre-clinical development and clinical development.The company's 2,000+ employees work across a number of therapeutic areas including CNS/neurology (e.g. Alzheimer's disease, Huntington's disease), metabolic diseases (e.g. Diabetes), Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Celgene, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Genentech, Roche, and more. On October 28, 2009, the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On September 24, 2018, Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology.

EVOTEC has been a target of short sellers for a while. The current short interest of 8.26% is significantly above the average of the last 12 months (4.35%). Recently, short selling has increased slightly.

History